Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice

Vaccine

Volumn 29, Issue 16, 2011, Pages 2968-2977

  Konduru, Krishnamurthy ^a   Bradfute, Steven B ^c   Jacques, Jerome ^a   Manangeeswaran, Mohanraj ^a   Nakamura, Siham ^a   Morshed, Sufi ^a   Wood, Steven C ^b   Bavari, Sina ^c   Kaplan, Gerardo G ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Fc fusion protein; Filoviridae; Glycoprotein; Interferon gamma; Mouse model; Neutralizing antibodies; T cell immunity; Vaccine; Zaire Ebola virus

Indexed keywords

EBOLA VACCINE; FILOVIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FILOVIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CHO CELLS; CRICETINAE; CRICETULUS; EBOLA VACCINES; EBOLAVIRUS; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLAQUE ASSAY; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 79953220686     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.113     Document Type: Article

References (50)

1. Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola viruses. Fields Virology 2007, 1409-1448. Lippincott Williams & Wilkins, Philadelphia, PA. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, M.A. Martin, R.A. Lamb, B. Roizman, S.E. Straus (Eds.).
2. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4(November (11)):e1000212.
3. Normile D. Emerging infectious diseases Scientists puzzle over Ebola-Reston virus in pigs. Science 2009, 323(January (5913)):451.
4. Volchkov V.E., Volchkova V.A., Dolnik O., Feldmann H., Klenk H.D. Polymorphism of filovirus glycoproteins. Adv Virus Res 2005, 64:359-381.
5. Feldmann H., Volchkov V.E., Volchkova V.A., Stroher U., Klenk H.D. Biosynthesis and role of filoviral glycoproteins. J Gen Virol 2001, 82(December (Pt 12)):2839-2848.
6. Takada A., Robison C., Goto H., Sanchez A., Murti K.G., Whitt M.A., et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A 1997, 94(December (26)):14764-14769.
7. Volchkov V.E., Feldmann H., Volchkova V.A., Klenk H.D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 1998, 95(May (10)):5762-5767.
8. Jeffers S.A., Sanders D.A., Sanchez A. Covalent modifications of the ebola virus glycoprotein. J Virol 2002, 76(December (24)):12463-12472.
9. Feldmann H., Kiley M.P. Classification, structure, and replication of filoviruses. Curr Top Microbiol Immunol 1999, 235:1-21.
10. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006, 3(June (6)). e177.
11. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424(August (6949)):681-684.
12. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408(November (6812)):605-609.
13. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007, 81(June (12)):6379-6388.
14. Hevey M., Negley D., Pushko P., Smith J., Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998, 251(November (1)):28-37.
15. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Stroher U., Grolla A., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3(January (1)). e2.
16. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11(July (7)):786-790.
17. Halfmann P., Ebihara H., Marzi A., Hatta Y., Watanabe S., Suresh M., et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009, 83(April (8)):3810-3815.
18. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 2003, 100(December (26)):15889-15894.
19. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 2(November (196 Suppl)). S430-7.
20. Mellquist-Riemenschneider J.L., Garrison A.R., Geisbert J.B., Saikh K.U., Heidebrink K.D., Jahrling P.B., et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res 2003, 92(April (2)):187-193.
21. Zhang M.Y., Wang Y., Mankowski M.K., Ptak R.G., Dimitrov D.S. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 2009, 27(February (6)):857-863.
22. Guyre P.M., Graziano R.F., Goldstein J., Wallace P.K., Morganelli P.M., Wardwell K., et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 1997, 45(November-December (3-4)):146-148.
23. Chen H., Xu X., Jones I.M. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 2007, 4:33.
24. Silberstein E., Dveksler G., Kaplan G.G. Neutralization of hepatitis A virus (HAV) by an immunoadhesin containing the cysteine-rich region of HAV cellular receptor-1. J Virol 2001, 75(January (2)):717-725.
25. Buchholz U.J., Finke S., Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 1999, 73(January (1)):251-259.
26. Yang Z.Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000, 6(August (8)):886-889.
27. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287(March (5458)):1664-1666.
28. Lee J.E., Kuehne A., Abelson D.M., Fusco M.L., Hart M.K., Saphire E.O. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain. J Mol Biol 2008, 375(January (1)):202-216.
29. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 1995, 92(May (10)):4477-4481.
30. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004, 78(May (10)):5458-5465.
31. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998, 178(September (3)):651-661.
32. Bradfute S.B., Swanson P.E., Smith M.A., Watanabe E., McDunn J.E., Hotchkiss R.S., et al. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J Immunol 2010, 184(January (1)):327-335.
33. Warfield K.L., Swenson D.L., Negley D.L., Schmaljohn A.L., Aman M.J., Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004, 22(September (25-26)):3495-3502.
34. Olinger G.G., Bailey M.A., Dye J.M., Bakken R., Kuehne A., Kondig J., et al. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005, 79(November (22)):14189-14196.
35. Warfield K.L., Olinger G., Deal E.M., Swenson D.L., Bailey M., Negley D.L., et al. Induction of humoral and CD8+T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005, 175(July (2)):1184-1191.
36. Chamow S.M., Ashkenazi A. Immunoadhesins: principles and applications. Trends Biotechnol 1996, 14(February (2)):52-60.
37. Hood C.L., Abraham J., Boyington J.C., Leung K., Kwong P.D., Nabel G.J. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 2010, 84(March (6)):2972-2982.
38. Ito H., Watanabe S., Sanchez A., Whitt M.A., Kawaoka Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol 1999, 73(October (10)):8907-8912.
39. Ito H., Watanabe S., Takada A., Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 2001, 75(February (3)):1576-1580.
40. Nanbo A., Imai M., Watanabe S., Noda T., Takahashi K., Neumann G., et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 2010, 6.(9).
41. Takada A., Feldmann H., Stroeher U., Bray M., Watanabe S., Ito H., et al. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 2003, 77(January (2)):1069-1074.
42. Geisbert T.W., Daddario-Dicaprio K.M., Geisbert J.B., Reed D.S., Feldmann F., Grolla A., et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008, 26(December (52)):6894-6900.
43. Geisbert T.W., Daddario-Dicaprio K.M., Lewis M.G., Geisbert J.B., Grolla A., Leung A., et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008, 4(November (11)). e1000225.
44. Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J., Geisbert J.B., Leung A., Feldmann F., et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008, 82(June (11)):5664-5668.
45. Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009, 83(July (14)):7296-7304.
46. Geisbert T.W., Hensley L.E., Geisbert J.B., Leung A., Johnson J.C., Grolla A., et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010, 16(July (7)):1119-1122.
47. Daddario-DiCaprio K.M., Geisbert T.W., Geisbert J.B., Stroher U., Hensley L.E., Grolla A., et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006, 80(October (19)):9659-9666.
48. Daddario-DiCaprio K.M., Geisbert T.W., Stroher U., Geisbert J.B., Grolla A., Fritz E.A., et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006, 367(April (9520)):1399-1404.
49. Hensley L.E., Mulangu S., Asiedu C., Johnson J., Honko A.N., Stanley D., et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010, 6(May (5)). e1000904.
50. Hevey M., Negley D., Geisbert J., Jahrling P., Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997, 239(December (1)):206-216.